TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer.

ABSTRACT

BACKGROUND: TMPRSS2ERG gene aberration may be a novel marker that improves risk stratification of prostate cancer before definitive cancer therapy, but studies have been inconclusive. METHODS: The study cohort consisted of 202 operable prostate cancer Slovenian patients who underwent laparoscopic radical prostatectomy. We retrospectively constructed tissue microarrays of their prostatic specimens for fluorescence in situ hybridization, with appropriate signals obtained in 148 patients for subsequent statistical analyses. RESULTS: The following genetic aberrations were found TMPRSS2ERG fusion, TMPRSS2 split (a non-ERG translocation) and ERG split (an ERG translocation without involvement of TMPRSS2). TMPRSS2ERG gene fusion happened in 63 patients (42 %), TMPRSS2 split in 12 patients and ERG split in 8 patients. Association was tested between TMPRSS2ERG gene fusion and several clinicopathological variables, i.e., pT stage, extended lymph node dissection status, and Gleason score, correcting for multiple comparisons. Only the association with pT stage was significant at p = 0.05 Of 62 patients with pT3 stage, 34 (55 %) had TMPRSS2ERG gene fusion. In pT3 stage patients, stronger (but not significant) association between eLND status and TMPRSS2ERG gene fusion was detected. We detected TMPRSS2ERG gene fusion in 64 % of the pT3 stage patients where we did not perform an extended lymph node dissection. CONCLUSIONS: Our results indicate that it is possible to predict pT3 stage at final histology from TMPRSS2ERG gene fusion at initial core needle biopsy. FISH determination of TMPRSS2ERG gene fusion may be particularly useful for patients scheduled to undergo a radical prostatectomy in order to improve oncological and functional results.